Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alex N Bullock

Showing results (41-50 of 115) with videos related to

Pageof 12
Sort By:
Bone|November 4, 2010
A novel ACVR1 mutation in the glycine/serine-rich domain found in the most benign case of a fibrodysplasia ossificans progressiva variant reported to dateCelia L Gregson, Peter Hollingworth, Martin Williams, et al.
The Biochemical Journal|October 26, 2019
Lessons from LIMK1 enzymology and their impact on inhibitor designEidarus Salah, Deep Chatterjee, Alessandra Beltrami, et al.
The Journal of Biological Chemistry|March 7, 2007
Interaction of hydroxylated collagen IV with the von hippel-lindau tumor suppressorAlexandra Grosfeld, Ineke P Stolze, Matthew E Cockman, et al.
Journal of Medicinal Chemistry|August 8, 2014
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutantsAgustin H Mohedas, You Wang, Caroline E Sanvitale, et al.
Journal of Medicinal Chemistry|December 6, 2011
7,8-dichloro-1-oxo-β-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modesKilian Huber, Laurent Brault, Oleg Fedorov, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 25, 2012
The p53 cofactor Strap exhibits an unexpected TPR motif and oligonucleotide-binding (OB)-fold structureCassandra J Adams, Ashley C W Pike, Sandra Maniam, et al.
Plos One|October 21, 2009
Crystal structure of the PIM2 kinase in complex with an organoruthenium inhibitorAlex N Bullock, Santina Russo, Ann Amos, et al.
ACS Chemical Biology|March 17, 2020
A Highly Selective Chemical Probe for Activin Receptor-like Kinases ALK4 and ALK5Thomas Hanke, Jong Fu Wong, Benedict-Tilman Berger, et al.
Journal of Medicinal Chemistry|October 1, 2009
Synthesis, kinase inhibitory potencies, and in vitro antiproliferative evaluation of new Pim kinase inhibitorsRufine Akué-Gédu, Emilie Rossignol, Stéphane Azzaro, et al.
The Journal of Biological Chemistry|September 15, 2012
Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressivaApirat Chaikuad, Ivan Alfano, Georgina Kerr, et al.
Pageof 12

Showing results (41-50 of 115) with videos related to

Sort By:
Pageof 12
Bone|November 4, 2010
A novel ACVR1 mutation in the glycine/serine-rich domain found in the most benign case of a fibrodysplasia ossificans progressiva variant reported to dateCelia L Gregson, Peter Hollingworth, Martin Williams, et al.
The Biochemical Journal|October 26, 2019
Lessons from LIMK1 enzymology and their impact on inhibitor designEidarus Salah, Deep Chatterjee, Alessandra Beltrami, et al.
The Journal of Biological Chemistry|March 7, 2007
Interaction of hydroxylated collagen IV with the von hippel-lindau tumor suppressorAlexandra Grosfeld, Ineke P Stolze, Matthew E Cockman, et al.
Journal of Medicinal Chemistry|August 8, 2014
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutantsAgustin H Mohedas, You Wang, Caroline E Sanvitale, et al.
Journal of Medicinal Chemistry|December 6, 2011
7,8-dichloro-1-oxo-β-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modesKilian Huber, Laurent Brault, Oleg Fedorov, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 25, 2012
The p53 cofactor Strap exhibits an unexpected TPR motif and oligonucleotide-binding (OB)-fold structureCassandra J Adams, Ashley C W Pike, Sandra Maniam, et al.
Plos One|October 21, 2009
Crystal structure of the PIM2 kinase in complex with an organoruthenium inhibitorAlex N Bullock, Santina Russo, Ann Amos, et al.
ACS Chemical Biology|March 17, 2020
A Highly Selective Chemical Probe for Activin Receptor-like Kinases ALK4 and ALK5Thomas Hanke, Jong Fu Wong, Benedict-Tilman Berger, et al.
Journal of Medicinal Chemistry|October 1, 2009
Synthesis, kinase inhibitory potencies, and in vitro antiproliferative evaluation of new Pim kinase inhibitorsRufine Akué-Gédu, Emilie Rossignol, Stéphane Azzaro, et al.
The Journal of Biological Chemistry|September 15, 2012
Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressivaApirat Chaikuad, Ivan Alfano, Georgina Kerr, et al.
Pageof 12